Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
MYD88 L265P
i
Other names:
MYD88, MYD88 Innate Immune Signal Transduction Adaptor, Myeloid Differentiation Primary Response Protein MyD88, Myeloid Differentiation Primary Response Gene (88), Myeloid Differentiation Primary Response 88, Mutant Myeloid Differentiation Primary Response 88, MYD88D
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
4615
Related biomarkers:
Expression
Mutation
Others
‹
›
Associations
News
Trials
VERI cancer hierarchy
Reset Filters
MYD88 L265P
Waldenstrom Macroglobulinemia
MYD88 L265P
Waldenstrom Macroglobulinemia
zanubrutinib
Sensitive: B - Late Trials
zanubrutinib
Sensitive
:
B
zanubrutinib
Sensitive: B - Late Trials
zanubrutinib
Sensitive
:
B
MYD88 L265P
Waldenstrom Macroglobulinemia
MYD88 L265P
Waldenstrom Macroglobulinemia
rituximab + ixazomib
Sensitive: C2 – Inclusion Criteria
rituximab + ixazomib
Sensitive
:
C2
rituximab + ixazomib
Sensitive: C2 – Inclusion Criteria
rituximab + ixazomib
Sensitive
:
C2
MYD88 L265P
Waldenstrom Macroglobulinemia
MYD88 L265P
Waldenstrom Macroglobulinemia
venetoclax
Sensitive: C3 – Early Trials
venetoclax
Sensitive
:
C3
venetoclax
Sensitive: C3 – Early Trials
venetoclax
Sensitive
:
C3
MYD88 L265P
Lymphoma
MYD88 L265P
Lymphoma
ibrutinib
Sensitive: C3 – Early Trials
ibrutinib
Sensitive
:
C3
ibrutinib
Sensitive: C3 – Early Trials
ibrutinib
Sensitive
:
C3
MYD88 L265P
Marginal Zone Lymphoma
MYD88 L265P
Marginal Zone Lymphoma
ibrutinib
Sensitive: C3 – Early Trials
ibrutinib
Sensitive
:
C3
ibrutinib
Sensitive: C3 – Early Trials
ibrutinib
Sensitive
:
C3
MYD88 L265P
Waldenstrom Macroglobulinemia
MYD88 L265P
Waldenstrom Macroglobulinemia
daratumumab
Sensitive: C3 – Early Trials
daratumumab
Sensitive
:
C3
daratumumab
Sensitive: C3 – Early Trials
daratumumab
Sensitive
:
C3
MYD88 L265P
Diffuse Large B Cell Lymphoma
MYD88 L265P
Diffuse Large B Cell Lymphoma
rituximab
Resistant: C3 – Early Trials
rituximab
Resistant
:
C3
rituximab
Resistant: C3 – Early Trials
rituximab
Resistant
:
C3
MYD88 L265P
Waldenstrom Macroglobulinemia
MYD88 L265P
Waldenstrom Macroglobulinemia
mavorixafor
Sensitive: C3 – Early Trials
mavorixafor
Sensitive
:
C3
mavorixafor
Sensitive: C3 – Early Trials
mavorixafor
Sensitive
:
C3
MYD88 L265P
Waldenstrom Macroglobulinemia
MYD88 L265P
Waldenstrom Macroglobulinemia
orelabrutinib
Sensitive: C3 – Early Trials
orelabrutinib
Sensitive
:
C3
orelabrutinib
Sensitive: C3 – Early Trials
orelabrutinib
Sensitive
:
C3
MYD88 L265P
Non-Hodgkin’s Lymphoma
MYD88 L265P
Non-Hodgkin’s Lymphoma
rituximab
Resistant: C3 – Early Trials
rituximab
Resistant
:
C3
rituximab
Resistant: C3 – Early Trials
rituximab
Resistant
:
C3
MYD88 L265P
Diffuse Large B Cell Lymphoma
MYD88 L265P
Diffuse Large B Cell Lymphoma
Sensitive: C3 – Early Trials
Sensitive
:
C3
Sensitive: C3 – Early Trials
Sensitive
:
C3
MYD88 L265P
Multiple Myeloma
MYD88 L265P
Multiple Myeloma
lenalidomide + bortezomib
Sensitive: C4 – Case Studies
lenalidomide + bortezomib
Sensitive
:
C4
lenalidomide + bortezomib
Sensitive: C4 – Case Studies
lenalidomide + bortezomib
Sensitive
:
C4
MYD88 L265P
Diffuse Large B Cell Lymphoma
MYD88 L265P
Diffuse Large B Cell Lymphoma
KT-413
Sensitive: D – Preclinical
KT-413
Sensitive
:
D
KT-413
Sensitive: D – Preclinical
KT-413
Sensitive
:
D
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login